N-(Cbz)-methanesulfonamide | 90903-98-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(Cbz)-methanesulfonamide
• 英文别名: Benzyl (methanesulfonyl)carbamate；benzyl N-methylsulfonylcarbamate
• CAS: 90903-98-3
• 化学式: C₉H₁₁NO₄S
• 分子量: 229.257
• InChiKey: REWRGJSWLNPCNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(Cbz)-methanesulfonamide 、 (S)-2-Iodomethyl-4-isobutyl-5-methyl-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Inhibition of serine proteases by functionalized sulfonamides coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold

  摘要：

  A challenge associated with drug design is the development of selective inhibitors of proteases (serine or cysteine) that exhibit the same primary substrate specificity, that is, show a preference for the same P-1 residue. While these proteases have similar active sites, nevertheless there are subtle differences in their S and S' subsites which can be exploited. We describe herein for the first time the use of functionalized sulfonamides as a design and diversity element which, when coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold yields potent, time-dependent inhibitors of the serine proteases human leukocyte elastase (HLE), proteinase 3 (PR 3) and cathepsin G(Cat G). Our preliminary findings suggest that (a) appending to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold recognition and diversity elements that interact with both the S and S' subsites of a target protease may result in optimal enzyme selectivity and potency and, (b) functionalized sulfonamides constitute a powerful design and diversity element with low intrinsic chemical reactivity and potentially wide applicability (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00037-2
• 作为产物：
  描述：

  甲基磺酰胺 、 氯甲酸苄酯 在 4-二甲氨基吡啶 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以57%的产率得到N-(Cbz)-methanesulfonamide
  参考文献：
  名称：

  N-（磺酰基）氨基甲酸酯的简便制备

  摘要：

  N-（磺酰基）氨基甲酸酯，在光延反应中有用的N-亲核试剂，可以通过使磺酰胺与4-（二甲基氨基）吡啶催化的氯甲酸酯（或二碳酸酯）反应而容易地制备。

  DOI：

  10.1016/0040-4039(94)85058-5

文献信息

• [EN] CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE<br/>[FR] INHIBITEURS CYCLIQUES DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1 BASÉE SUR LA STRUCTURE 1,3-OXAZINAN-2-ONE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2011011123A1

  公开（公告）日：2011-01-27

  This invention relates to substitued 1, 3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B)的取代1,3-噁唑-2-酮化合物，以及其药学上可接受的盐和药物组合物，用于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法的用途。
• Facile preparation of N-(sulfonyl)carbamates
  作者：Bernard R. Neustadt

  DOI：10.1016/0040-4039(94)85058-5

  日期：1994.1

  N-(Sulfonyl)carbamates, useful N-nucleophiles in the Mitsunobu reaction, can be prepared readily by reaction of sulfonamides with chloroformates (or dicarbonates) catalyzed by 4-(dimethylamino)pyridine.

  N-（磺酰基）氨基甲酸酯，在光延反应中有用的N-亲核试剂，可以通过使磺酰胺与4-（二甲基氨基）吡啶催化的氯甲酸酯（或二碳酸酯）反应而容易地制备。
• PSMA imaging agents
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：US10894807B2

  公开（公告）日：2021-01-19

  Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

  本研究公开了靶向前列腺特异性膜抗原（PSMA）的化合物和成像剂。 还公开了化合物和成像剂的合成方法以及 PSMA 的成像方法。 所公开的成像剂适用于 PET 和 SPECT 成像。
• AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1230210A1

  公开（公告）日：2002-08-14
• CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2440537A1

  公开（公告）日：2012-04-18